Melanocortin receptor agonist - Palatin Technologies
Alternative Names: MCr agonist - Palatin TechnologiesLatest Information Update: 29 Aug 2023
At a glance
- Originator Palatin Technologies
- Class Urologics
- Mechanism of Action Melanocortin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Diabetic nephropathies